Astra Zeneca
 |
|
| Public limited company | |
| Traded as | : Nasdaq Stockholm: AZN : AZN |
| Industry |
Pharmaceutical Biotechnology |
| Predecessor |
Astra AB Zeneca Group plc |
| Founded | April 6, 1999 |
| Headquarters | Cambridge, England |
|
Area served
|
Global |
|
Key people
|
Leif Johansson (Chairman) Pascal Soriot (CEO) |
| Products | Pharmaceutical products |
| Revenue | US$24.708 billion (2015) |
| US$4.114 billion(2015) | |
| US$2.826 billion (2015) | |
| Total assets | US$60.12 billion (2016) |
|
Number of employees
|
50,000 (2014) |
| Subsidiaries | MedImmune |
| Website | www.astrazeneca.com |
AstraZeneca plc is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including of Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca has a primary listing on the and is a constituent of the FTSE 100 Index. It has secondary listings on the and the OMX exchange.
...
Wikipedia